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A B S T R A C T   
Superoxide dismutase (SOD) is known to be protective against oxidative stress-mediated skin dysfunction. Here 
we explore the potential therapeutic activities of RM191A, a novel SOD mimetic, on skin. RM191A is a water- 
soluble dimeric copper (Cu2+-Cu3+)-centred polyglycine coordination complex. It displays 10-fold higher su-
peroxide quenching activity compared to SOD as well as significant antioxidant, anti-inflammatory and immu-
nomodulatory activities through beneficial modulation of several significant inflammatory cytokines in vitro and 
in vivo. 
We tested the therapeutic potential of RM191A in a topical gel using a human skin explant model and observed 
that it significantly inhibits UV-induced DNA damage in the epidermis and dermis, including cyclobutane py-
rimidine dimers (CPD), 8-oxo-guanine (8-oxoG) and 8-nitroguanine (8NGO). RM191A topical gel is found to be 
non-toxic, non-teratogenic and readily distributed in the body of mice. Moreover, it significantly accelerates 
excisional wound healing, reduces 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation and at-
tenuates age-associated oxidative stress in skin, demonstrating both skin regenerative and geroprotective 
properties of RM191A.   
1. Introduction 
Our skin acts as the first barrier of defence against various infections, 
trauma and environmental factors. Risk factors like ultraviolet (UV) 
radiation, environmental pollutants, xenobiotics, aging, wounds, 
chronic inflammation and inflammatory skin diseases, such as psoriasis 
and atopic dermatitis, are major impediments against the proper 
maintenance of the skin barrier [1–4]. Oxidative stress, which com-
promises proper skin integrity, is one of the most common features 
among these various risk factors [5–7]. An over-abundance of oxidants 
or catalysts producing free radicals, such as reactive oxygen species 
(ROS) and reactive nitrogen species (RNS), and in parallel the failure of 
the endogenous anti-oxidant defence system in skin cells, primarily 
contribute to the formation of oxidative stress in skin [8–10]. Further-
more, oxidative stress and inflammation are closely interconnected 
pathophysiological processes that are known participants in the patho-
genesis of numerous skin diseases [11–14]. Inhibition of oxidative stress 
and inflammation is therefore important for maintenance of normal skin 
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function. 
Superoxide dismutase (SOD) enzymes catalyze the disproportion-
ation of the cytotoxic superoxide (O2. -) free radical to hydrogen peroxide 
and oxygen and play a significant role in the attenuation of oxidative 
stress in our body [15]. SODs have been reported to be protective against 
many skin disorders [16]. They sequester free radicals which are formed 
following UV exposure and have the potential to damage our DNA. Such 
DNA damage has been shown to be a major contributing factor to skin 
carcinogenesis. Due to its powerful antioxidant potential, endogenous 
SOD also exhibits potent anti-inflammatory activities by inhibiting the 
expression of ROS-sensitive transcription factors [17]. SOD plays a 
major role in wound healing [18,19]. For these reasons, exogenous SOD 
was contemplated as a therapeutic agent for the treatment of various 
skin disorders. However, the lack of clinical development of exogenous 
SOD is due to its large size (molecular weight ≈ 30 kDa), low cell 
permeability, short circulating half-life, antigenicity, and high 
manufacturing costs [20]. To overcome these issues, much focus has 
been placed on the synthesis of low-molecular-weight, stable com-
pounds that mimic SOD’s antioxidant activity. 
There are three kinds of SOD enzymes. SOD2 is localized in mito-
chondria and contains manganese. Both cytosolic SOD1 and extracel-
lular SOD3 enzymes contain a redox active copper atom (Cu2+), which is 
fundamental to the dismutation of the superoxide free radical, and a zinc 
atom [21–23]. Interestingly, it has been established that if the zinc atom 
of either SOD is replaced with a copper atom, this di-copper form has the 
same free radical/superoxide scavenging activity as the endogenous 
Cu/Zn enzymes [24]. A significant number of the SOD mimetics re-
ported in the literature focus on replicating the activity of SOD2. These 
include a variety of manganese porphyrin complexes, manganese (II) 
penta-azamacrocyclic complexes, and manganese (III) salen complexes 
[25]. Topical application of these SOD mimetics demonstrated potential 
benefits for the treatment of skin disorders [26–28]. Only a small 
number of SOD mimetics utilising the unique copper-based bivalent 
configuration of SOD1 have been reported, however, their biological 
activities were never demonstrated [24,29,30]. 
Here we report for the first time, a highly stable, unique copper 
(Cu2+-Cu3+)-centred polyglycine coordination complex – RM191A, 
which has been demonstrated through extensive analytical, in vitro and 
in vivo evaluation to possess robust antioxidant, anti-inflammatory and 
immunomodulatory activities. Our work indicates biological activity of 
topically applied RM191A across a broad spectrum of skin disorders. 
Specifically, we report protection of the epidermis, dermis and associ-
ated DNA following exposure to UV radiation in human skin explants; 
acceleration of wound healing; and significant anti-inflammatory and 
antioxidant activities in the skin of young and old mice. We posit that 
these activities are a result of the complex’s SOD-like activity, immu-
nomodulation and beneficial alteration of a number of important sig-
nalling pathways, including attenuation of key inflammatory cytokines. 
2. Material and methods 
RM191A Synthesis. RM191A was synthesized according to a pro-
prietary protocol patented by RR MedSciences. RM191A gel formulation 
consists of 21 mg of RM191A in 1 mL of hydrogel base (Vehicle). 
Elemental analysis. Elemental microanalysis was performed using 
2400 CHNS elemental analyzer (PerkinElmer). 
FTIR. FTIR spectroscopy was performed using Nicolet iS5 FTIR 
Spectrometer (Thermofisher). 
Cryo-TEM. After diluting 2 mg of the sample into 1 mL of pure water 
(500 dilution), the sample (6 μL) was pipetted onto 300 mesh copper 
grids with a lacey formvar film (GSCu300FL-50, ProSciTech, Australia). 
The sample droplet was allowed to equilibrate for 30 s at room tem-
perature and 90% relative humidity, before being blotted from one side 
for 1.8 s. The blotted grid was subsequently plunged into liquid ethane 
held at − 174 ◦C, excess ethane was blotted away with a piece of pre- 
cooled filter paper, and the vitrified grid stored in liquid nitrogen. The 
samples were then analysed by cryo-TEM. 
DOSY. The DOSY experiments were carried out on a Bruker AVANCE 
400 MHz NMR in D2O at 25 ◦C with a BBFO probe using 3-9-19 water 
suppression. 
X-ray crystallography. Blue solid of RM191A was crystallised from 
supernatant generated by addition of ethanol to reaction mix. Powder 
diffraction was performed on a Panalytical Empyrean Bragg-Brentano 
geometry instrument fitted with a cobalt X-ray source. 
Measurement of SOD activity. We employed a modified version of 
the method described by Beauchamp and Fridovich [31]. The objective 
was to create a reaction mixture that successfully generates known 
quantities of the O2. - free radical but does so at a pH at which RM191A is 
stable (pH 6.5–7.8). Nitro Blue Tetrazolium (NBT) was selected as an 
indicator to measure and compare the superoxide scavenging activities 
of both bovine SOD and RM191A. This assay utilized photochemical 
events to generate O2. - in a phosphate buffered solution of acetone and 
isopropanol which was then irradiated by high energy UV light at 254 
nm (Mercury Vapour Lamp) to create O2. - in the solution. SOD and 
SOD-like substances inhibit the formation of the blue formazan by 
neutralising the superoxide free radicals as they are forming. Blue for-
mazan has a characteristic UV absorbance at 560 nm. UV absorbances of 
the reaction solutions were measured at 560 nm following irradiation 
with UV light to determine the superoxide free radical scavenging ac-
tivity in situ of both bovine SOD and RM191A. The UV–vis spectrum of 
both SOD and RM191A did not exhibit any absorbance at 560 nm 
(Fig. S2B). The reaction solution consists of 0.5 mL of 200 μmol/L NBT in 
phosphate buffer (pH = 7.8) and 0.5 mL of a 200 μmol/L solution of the 
test compound in 5.0 mL of 5 mol/L isopropanol. 15 mg acetone (20 μL) 
was added to begin the reaction. The reaction mixture was placed in UV 
light at 254 nm (mercury vapour lamp) for 1 min and then transferred to 
a spectrometer to measure absorbance at 560 nm. The assay was 
repeated by adding, 1.0, 1.25, 1.5, 1.75, 2.0 mL of a 200 μmol/L solution 
of the test compound bringing total volume to 5.0 mL with 5 mol/L 
isopropanol. 
Cells. N27 cells were cultured in RPMI 1640 medium supplemented 
with 10% (v/v) fetal calf serum (FCS), 2 mM L-glutamine and penicillin/ 
streptomycin solution at 37 ◦C with 5% CO2. RAW 264.7 cells were 
cultured in DMEM medium supplemented with 10% FCS and 1% Pen/ 
Strep at 37 ◦C with 5% CO2. Human umbilical vein endothelial cells 
(HUVEC) and hCMEC/D3 were cultured in RPMI + 10% FCS at 37 ◦C 
with 3% O2 and 5% CO2. Adult normal human dermal fibroblasts 
(NHDF) were cultured in FGM-2 fibroblast growth medium-2 (Lonza) at 
37 ◦C with 3% O2 and 5% CO2. RAW 264.7 cells (106) were stimulated 
with LPS (10 ng/mL) and treated with RM191A (2.1 μg/mL) or Vehicle 
for 6 or 24 h. 
Cell viability. Cell viability was assessed using propidium iodide 
exclusion assay as described before [32]. Briefly, cells (0.1 × 105 cells) 
were seeded in a 48-well plate and incubated with different concentra-
tions of RM191A or Vehicle for 24 h. After 24 h, cells were trypsinized, 
stained with PI (10 μg/mL) and the number of PI negative (PI -ve) cells 
were determined by flow cytometry (BD FACSCanto II). In hydrogen 
peroxide-mediated oxidative stress assay, N27 cells were first exposed to 
200 μM hydrogen peroxide for 30 min and then treated with 21 μg/mL 
RM191A (or Vehicle) for 4 h, after which cell viability was measured 
using flow cytometry. Alternatively, cell viability was determined using 
MTT assay kit (Sigma Aldrich) according to manufacturer’s protocol. 
Measurement of intracellular ROS. ROS generation in LPS- 
stimulated RAW 264.7 cells was determined as previously reported 
[33]. After 6 h of LPS stimulation, the fluorescent dye CM-H2DCFDA 
(final concentration 10 μl of 20 μM) was added to cells and incubated for 
30 min in a CO2 incubator to measure the intracellular ROS produced in 
these cells. After incubation, the cells were washed with cold phosphate 
buffered saline (PBS) and the amount of ROS was analysed by flow 
cytometry. 
Measurement of NO. Nitrite concentrations in cell culture super-
natants and tissues were determined using a Nitrate/Nitrite Colorimetric 
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Assay Kit (Cayman Chemical) according to the manufacturer’s in-
structions. In short, nitrate reductase was used to enzymatically convert 
all nitrate to nitrite. Next, Griess reagents R1 and R2 were used to 
produce deep purple coloured compound and detected using a plate 
reader, absorbance at 540 nm. The skin and ear tissue lysates were 
prepared in PBS with 1% Triton-X and protease inhibitors. 
Real-time quantitative PCR. RNA extraction from cells and tissues 
was performed using a RNeasy Plus Mini Kit (Qiagen) according to the 
manufacturer’s instructions. The cDNA was synthesized using iScript 
cDNA Synthesis Kit (Bio Rad). PCR amplification of cDNA with gene 
specific primers was performed using FastStart Universal SYBR Green 
Master (ROX) (Sigma Aldrich). Fold changes in genes were calculated 
using delta delta CT method. HPRT was used as a housekeeper gene. The 
list of primers is shown in Table S6. 
Gene expression analysis. Gene expression in NHDF was per-
formed at Bosch Institute, Sydney. NHDF were treated with RM191A 
(21 μg/mL) or Vehicle for 24 h. Mature RNA was isolated using an RNA 
extraction kit (Qiagen) according to the manufacturer’s instructions. 
RNA quality was determined using a spectrophotometer and was reverse 
transcribed using a cDNA conversion kit (Qiagen). The cDNA was used 
on the real-time RT2 Profiler PCR Arrays (QIAGEN, Cat. no. PAHS-065Y, 
PAHS-022Z, PAHS-162Z) in combination with RT2 SYBR® Green qPCR 
Mastermix (Cat. no. 330529). Fold changes in genes were calculated 
using delta delta CT method in data analysis web portal (http://www. 
qiagen.com/geneglobe). The gene expression for each group was ana-
lysed in two different experiments. The heat map was generated using 
Morpheus software (Broad Institute). The CT cut-off was set to 36. 
Blood-brain-barrier transmission assay. hCMEC/D3 cell line 
derived from human brain endothelial cells were seeded onto membrane 
of 24 mm Transwells with 4 μm pores (Corning) coated with 3% collagen 
at 4.5 × 105 cells/well and grown to confluence in RPMI + 10% FCS 
medium. RM191A was added to the top of the transwell at 8.4, 16.8, 
33.6 and 168 μg/mL. After 2 and 6 h, media from top and bottom 
chambers of the transwells were collected and stored at − 20 ◦C until 
further analysis. The media was then analysed by HPLC (Phenomenex 
Luna HILIC Analytical Column 3 μm, 2 × 100 mm, mobile phase: 85/15 
ACN/NH4 formate buffer (0.1 M. pH 4.3)). 
UV exposure and RM191A treatment in skin explants. All ex-
periments were performed according to procedures approved by Uni-
versity of Sydney Human Ethics Committee. Human skin explants were 
obtained with consent from patients undergoing elective surgery. The 
protocol for obtaining skin explants and for their use to examine pho-
toprotective effects of test agents was described in Song et al., with some 
minor changes [34]. In brief, skin removed at elective surgery was 
cleaned, subcutaneous fat removed and cut into pieces to produce 
multiple pieces approx. 4–6 mm x 4–6 mm, with each explant placed in 
one well of a 96 well plate in RPMI 1640 media containing 10% FCS. 
Skin explants in triplicate were used for each treatment point. The DNA 
damage was analysed after 3 h incubation period. 
Skin was subjected to solar simulated UV-radiation, as previously 
described [34,35]. The spectral output of this solar simulator compared 
with sunlight is shown in Fig. S3A. Treatments, as indicated below, were 
applied to the epidermal surface of the explant. Sham wells were treated 
in a similar manner to UV-exposed wells, including media changes and 
treatments, but were covered with foil and not exposed to UV. RM191A 
or Vehicle was used with two protocols. In Protocol 1, 1.5 μL of 
RM191A/Vehicle was applied to the surface of the explant 10–15 min 
prior to UV exposure, then again immediately after UV and then at 0.5, 
1.5, and 2.5 h. In Protocol 2, 1.5 μL of RM191A/Vehicle was applied to 
the surface of the explant immediately after UV exposure, then at 1, 2, 
2.5 h. The positive control treatment was 1,25 dihydroxyvitamin D3, (1, 
25D) [34], which was dissolved in spectroscopic grade ethanol (1,25D 
Vehicle) at a final concentration of 1 nM and 0.1% v/v ethanol in RPMI 
media with 10% v/v FCS. Both 1,25D and 1,25D Vehicle were also 
applied immediately after UV. Sham wells consisted of 1,25D Vehicle, 1, 
25D, Vehicle 1 (Protocol 1 only) and RM191A 1 (Protocol 1 only). There 
were insufficient explants to do sham wells of RM191A and Vehicle with 
Protocol 2 at both time points. UV-exposed wells consisted of 1,25D 
Vehicle, 1,25D, Vehicle 1, Vehicle 2, RM191A 1 and RM191A 2. 
Animal experiments. All experiments were performed according to 
procedures approved by University of New South Wales (UNSW) Animal 
Care and Ethics Committee. Male C57BL/6 mice (Australian Bio-
Resources, Mossvale, NSW and Animal Resource Centre, Canning Vale, 
WA, Australia) were housed in the UNSW Biological Resource Centre 
(BRC) at 21 ◦C ± 2, with a 12 h/12 h dark/light cycle and were fed 
standard chow diet. 
RM191A treatment. One day prior to the application of RM191A, 
male mice were anaesthetised and hair on the dorsal surface was 
removed with a clipper. The shaved area was then cleaned with betadine 
solution, wiped with an alcohol swap and dried for a few seconds. The 
following day, the animals were briefly anaesthetised and RM191A at 
different concentrations (diluted in gel to make up to 50 μL) was applied 
topically. This step was repeated for 3 and 29 consecutive days for short- 
term and long-term treatment protocols, respectively. On the 4th and 
30th day, the animals were euthanized, tissues were harvested, and flash 
frozen in liquid nitrogen. The overall health of the animals was moni-
tored daily and weights were recorded daily until euthanized. For the 
short-term treatment protocol, the treatment groups consisted of Vehicle 
and RM191A (0.19, 0.38, 0.76, 1.33 and 1.9 mL/kg). For long-term 
treatment protocol, the groups consisted of no gel, Vehicle and 
RM191A (0.19 mL/kg). Aged (102-week-old) female mice were shaved 
dorsally and 50 μL of RM191A (0.38 mL/kg) or Vehicle was applied 
topically for 7 consecutive days. The animals were euthanized on the 8th 
day. 
Teratogenicity study. Two females and a male (12 weeks of age) 
were housed in a cage for mating overnight and maintained on a 12-h 
light/dark cycle. The females were examined for the presence of 
vaginal plugs the following morning. If a plug was observed then the 
onset of gestation (gestation day GD 0) was considered to be 1:00 a.m. of 
the previous night, the midpoint of the dark cycle. On GD 4, the dam was 
weighed, dorsal surface was shaved and transferred to a separate cage 
for single housing for the rest of the period. RM191A (5 μL of 21 mg/mL 
RM191A in 45 μL of gel) was administrated daily dorsally until GD18. 
On GD19, all dams were euthanized by CO2 and the uterus with pups 
were removed. The maternal weight gain was determined by subtracting 
the body weight on GD0 from GD18. The litters were assessed by 
counting and measuring the weight. The morphology of litters was 
determined by μ-CT analysis (U-CT MILabs) after fixation in 10% 
formalin. 
Rotarod test. Motor coordination was assessed using the rotarod test 
as previously described [36]. In short, mice were acclimatized to a 
rotarod for 3 days in three trials lasting 2 min each at a constant speed of 
5 rpm. On the 4th day, the animals were subjected to three trials on the 
accelerating roller (4–40 rpm in 4 min) and the time that the mice 
remained was recorded. 
Rearing test. Mouse rearing test was performed as described pre-
viously [37]. Briefly, the mouse was placed in a clean transparent cyl-
inder (diameter: 12 cm, height: 15 cm) for 3 min and its forelimb activity 
while rearing against the wall of the arena was recorded. 
EchoMRI. Body composition (fat mass, lean mass, and total body 
water) was measured by EchoMRI (EchoMRI-900). 
RM191A time point study. One day prior to the application of 
RM191A on mice, the animals were anaesthetised and hair on the dorsal 
surface was removed with a clipper. The shaved area was then cleaned 
with betadine solution, wiped with alcohol swap and dried for a few 
seconds. Next day, the animals were briefly anaesthetised and 50 μL of 
RM191A in gel formulation (1.9 mL/kg RM191A) was applied topically. 
The animals were euthanized at 0, 15 min, 30 min, 1 h and 2 h post- 
treatment and tissues were harvested. 
ICP-MS. About 100 mg of tissue sample (50 μL in the case of plasma 
and urine) was transferred to a 10 mL polypropylene tube (Sarstedt), 
then 200 μl of concentrated nitric acid (HNO3) was added and incubated 
A. Shariev et al.                                                                                                                                                                                                                                 
Redox Biology 38 (2021) 101790
4
for 12 h at room temp with occasional shaking. After 12 h, the tube was 
heated at 80 ◦C moderately up to clearing (5 h) and cooled down to room 
temperature. 20 μl of hydrogen peroxide was added, and the tube was 
again heated up to 80 ◦C for 2 h. Next, the volume was made up to 10 mL 
with milliQ water. A blank standard was prepared in the same way. The 
samples were then analysed for copper using ICP-MS NEXion 
(PerkinElmer). 
Ear edema model. TPA (12-O-tetradecanoylphorbol-13-acetate)- 
induced mouse ear edema was generated according to a published 
protocol [38]. Briefly, 6 μg of TPA dissolved in 20 μL acetone was 
applied to the left ear of a mouse. 20 μL of acetone was applied to the 
right ear as vehicle control. Both ears were pre-treated with 50 μL of 
Vehicle or RM191A (2.1 mg/mL), 15 min prior to TPA or acetone 
application, and 10 min after TPA or acetone application. After 6 h, ear 
tissue was excised using a 5 mm biopsy punch and ear weight was 
measured. The ear samples were then fixed in 10% formalin or kept 
frozen at -80 ◦C. 
Wound regeneration model. Wound healing protocol in mice was 
performed as described previously, with minor modifications [39]. One 
day prior to wounding, the animals were anaesthetised and hair on the 
dorsal surface was removed with a clipper. The shaved area was then 
cleaned with betadine solution, wiped with an alcohol swab and dried 
for a few seconds. Next day, the animals were briefly anaesthetised, and 
a wound was created on the dorsal skin using a 10 mm biopsy punch. 
The picture of wound was captured, and the wound was covered with a 
semi-occlusive dressing (3 M Tegaderm). Two days after the wounding 
procedure, 50 μL of Vehicle or RM191A (2.1 mg/mL) was applied to the 
wound area and the application was repeated every 2 days. Each animal 
was singly housed during the entire procedure. The pictures of wounds 
were captured every 2 days and wound area was analysed using ImageJ 
software. 
Hematoxylin and eosin (H&E) staining. After fixation in paraffin, 
samples were stained with 0.1% Hematoxylin for 10 min, rinsed with 
dH2O, stained with Scott’s blue solution for 1 min and then washed with 
dH2O. The sections were then dipped in Eosin for 3 min, dehydrated 
through alcohol and cleared in xylene. The slides were mounted with 
DPX and imaged using a Zeiss Axio Scan Z1 (Zeiss) slide scanner. 
Toluidine blue staining. After fixation and subsequent paraffin 
embedding, samples were dewaxed and washed in dH2O. Sections were 
then stained with toluidine blue solution (0.1% in PBS, pH 2.0–2.5) for 
3 min. The sections were then dehydrated and cleared in xylene. The 
slides were then mounted with DPX and imaged using an electronic 
microscope. 
Masson trichrome staining. Following fixation, sections were 
stained with Bouin’s solution for 1 h at 56 ◦C, rinsed in dH2O and sub-
sequently stained through repeated dips of Celestine blue, Harris he-
matoxylin, Scott’s blue, Acid alcohol, Scott’s blue and Briebrich Scarlet. 
Next, the slides were rinsed in dH2O and left in 1% Phosphomolybdic 
acid until collagen decolourisation became apparent and stained further 
in Light green/Aniline blue, 1% acetic acid with quick dH2O washes 
between each stain. The slides were then mounted with DPX and imaged 
using an electronic microscope. 
Immunohistochemistry. Three or 24 h after irradiation, the huma 
skin explants were fixed, embedded in paraffin and sectioned before 
being deparaffinized and rehydrated for staining. Antigen retrieval was 
achieved with 10 mM citrate buffer. These sections were then stained as 
described for cyclobutane pyrimidine dimers (CPD), oxidative DNA 
damage in the form of 8-oxo-guanine (8-oxoG) and nitrosative DNA 
damage in the form of 8-nitroguanine (8NGO) [34]. Isotype controls 
were performed (without primary antibody). Immunohistochemistry 
was carried out and analysed using the Metamorph image analysis 
program as previously described [34], except that the results were 
expressed as mean pixel intensity – mean grey value in arbitrary units 
[35]. In addition to analysing nuclear staining in the epidermis, for 
8-oxoG and 8NGO, a separate analysis was performed on the upper layer 
of the dermis, where there were reasonable numbers of cells visible. 
Multiplex assay. Custom murine Luminex immunoassays for GRO- 
α, IL-1β, IL-6 and MCP-1 in cell culture supernatants and mouse serum 
were performed by Crux Biolabs (Bayswater, Australia). 
Statistics. Data are presented as mean ± SEM. Statistical signifi-
cance was performed using Student’s t-test or ANOVA with Tukey’s post 
hoc test. Statistical tests were performed using GraphPad Prism software. 
P values of less than 0.05 were considered statistically significant. 
3. Results 
3.1. Synthesis and characterization of RM191A 
Synthesis of RM191A yielded a dark blue-green aqueous solution, 
and when dried the compound contains 11.8% copper (Fig. 1A, Table 1). 
RM191A is a highly polar compound that is completely insoluble in non- 
polar solvents. Although the UV–visible absorption spectra of RM191A 
was similar to that of Cu-EDTA complex (Fig. S1A), RM191A exhibited 
an intense fluorescence emission peak at 440 nm (Fig. 1B). FTIR spectra 
of RM191A showed absorbances characteristic of amino and carboxylic 
acid functionalities (Fig. S1B). This information combined with the 
elemental analysis indicate that RM191A is a copper-amino acid chelate 
complex. 
To delineate the structure further, analysis via cryo-TEM was per-
formed in which RM191A showed unexpected black dots about 20–50 
nm in diameter in comparison with a blank sample, strongly suggesting 
the presence of large copper-containing complexes in this sample 
(Fig. 1C). This conclusion was also supported by NMN diffusion ordered 
spectroscopy (DOSY), in which the compound exhibited a large 
apparent increase in the chelate hydrodynamic radii suggesting that the 
proton signals seen in the 1H NMR of the copper chelate complex belong 
to a species that is oligomeric (Table 2, Fig. S1C). The hydrodynamic 
radius of Cu species in RM191A appeared to be at least 4.67 Å or a 
diameter of nearly 1 nm compared to 3.0 Å radius (0.6 nm diameter) for 
a standard Zn-EDTA complex. X-ray diffraction of crystalline RM191A 
showed a hydrated copper-polyglycine coordination complex where 
glycine-like ligands are shared between two copper atoms, resulting in a 
square planar and pyramidal geometry (Fig. 1D, Fig. S1D). Diffusion 
pulsed voltammetry confirmed the presence of both Cu2+ and Cu3+ ions 
in RM191A (Fig. 1E, Fig. S1E). Together, this data confirmed that 
RM191A was a Cu2+ and Cu3+ containing polyglycine coordination 
complex. 
3.2. RM191A has potent antioxidant and anti-inflammatory properties 
The interesting similarity of RM191A to the dimeric structure of 
SOD1 and presence of unique Cu2+/Cu3+ dipole led us to postulate that 
RM191A would be a highly efficient free radical scavenger, which could 
act in a similar manner to SOD. To prove our hypothesis, we measured 
and compared the superoxide scavenging activities of both bovine SOD 
and RM191A using a well-established assay [31]. The results showed 
that at 20 μM concentration, RM191A was 10 times more effective at 
neutralising superoxide free radicals than SOD (Fig. 2A). At 40 μM, the 
activity of RM191A exceeded that of SOD by 30 times. With increasing 
concentration, RM191A maintained the same neutralising activity, 
however, that of SOD decreased (Fig. S2A). This is not surprising as it 
has been reported that the ratio of antioxidant/pro-oxidant effects of 
SOD decreases as its concentration increases [40]. 
Next, we decided to test the bioactivity of RM191A in cells. For all 
subsequent experiments, RM191A was dissolved in a hydrogel (Vehicle). 
Upon treatment of N27 cells, an immortalized rat dopaminergic 
neuronal cell line [41], with different concentrations of RM191A and 
measuring the percentage of live cells by flow cytometry or MTT assay, 
the LD50 of RM191A was observed to be 210 μg/mL (Fig. 2B, Fig. S2C). 
Similarly, LD50 of RM191A for human umbilical vein endothelial cells 
(HUVEC) was found to be 210 μg/mL (Fig. S2D). In order to determine if 
RM191A could protect cells from ROS-mediated oxidative stress, N27 
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cells were first exposed to 200 μM hydrogen peroxide for 30 min and 
then treated with 21 μg/mL RM191A (or Vehicle) for 4 h. RM191A 
treatment increased the viability of cells by 24% when measured by flow 
cytometry, compared to the control (Fig. 2C). 
ROS is known to mediate inflammatory responses induced by a va-
riety of stimuli including lipopolysaccharide (LPS) [42,43]. Treatment 
of macrophage-like RAW 264.7 cells with exogenous SOD decreases 
LPS-induced ROS and RNS generation as well as down-regulates several 
inflammatory genes, including IL-1β, IL-6 and TNF-α [43,44]. To 
investigate if RM191A has similar effects, at first, we determined its 
toxicity in RAW 264.7 cells using flow cytometry and MTT assay. The 
LD50 of RM191A was 85 μg/mL in both assays (Fig. S2E, S2F, S2F). Next, 
RAW 264.7 cells were stimulated with LPS (10 ng/mL) and then treated 
with RM191A (2.1 μg/mL) or Vehicle only. After 6 h the amount of ROS 
was measured by flow cytometry. LPS stimulation resulted in a 42% 
increase in ROS level and treatment with RM191A decreased it to 36% 
(Fig. S2G). The production of RNS was determined by measuring the 
nitrous oxide (NO) level in the culture medium using Griess reagent. As 
shown in Fig. 2D, LPS induced a 15-fold increase in NO production after 
24 h in the Vehicle-treated group when compared to unstimulated RAW 
cells (Fig. 2D). However, RM191A treatment of LPS-stimulated group 
reduced the NO level by 75% compared to LPS/Vehicle-treated group. 
The mRNA levels of pro-inflammatory cytokines IL-1β, IL-6 and TNF-α 
were analysed by real time-quantitative PCR at 24 h. RM191A signifi-
cantly inhibited the expression of these cytokines, with that of TNF-α 
being reduced by 80% in LPS-stimulated groups (Fig. 2E). The inhibition 
of IL-1β was also observed in the protein level, where multiplex assay 
using the culture medium demonstrated an 89% reduction in IL-1β 
secretion from RM191A treated cells upon LPS stimulation when 
compared to the control (Fig. 2F). Although the mRNA level of NLRP3 
inflammasome was upregulated in LPS-stimulated, RM191A-treated 
cells compared to the control (Fig. S2H), it has been previously reported 
that RAW cells are defective in activation of NLRP3 due to the lack of 
ASC protein adaptor [45]. 
Given these data, we were curious to understand RM191A’s ability to 
affect oxidative stress and inflammatory pathways. To investigate this, 
adult normal human dermal fibroblasts (NHDF) were treated with 
RM191A and changes in gene expression in an unstimulated state 
compared to control were determined using PCR arrays. Toxicity anal-
ysis demonstrated that RM191A was well-tolerated by NHDF, with no 
evident cell death up to a dose of 210 μg/mL (Fig. S2I). Although 
RM191A treatment did not change the expression of SODs in NHDF, the 
expression of several genes that confer cellular protection against 
oxidative stress were significantly upregulated (Fig. S2J, Table S1). 
Notably, heme oxygenase (HMOX1), heat shock protein (HSPA1A) and 
thioredoxin reductase (TXNRD1) expression increased by 70, 7 and 5- 
fold respectively in RM191A-treated NHDF compared to the control. 
Amongst the inflammatory genes, CCL7, CXCR6, CCRL1 and CMKLR1 
were downregulated, while the expression of CCL26 and IL8 were 
upregulated in RM191A-treated NHDF (Fig. S2K, Table S2). These small 
changes in chemokines may be due to the fact that in basal condition, the 
inflammatory genes are not upregulated in NHDF and therefore the 
protective effects of RM191A were not obvious. Repeating the experi-
ment where the NHDF are subjected to oxidative stress by external 
stimuli would be ideal to demonstrate the anti-inflammatory effects of 
Fig. 1. Synthesis and characterization of RM191A. 
(A) Picture of RM191A solution. (B) Fluorescence 
emission spectrum of RM191A and Cu-EDTA with 
peak at 440 nm. (C) Cryo-TEM images of blank (top) 
and RM191A (bottom). (D) Structure of RM191A 
crystal from X-ray single-crystal analysis (Red = ox-
ygen, blue = nitrogen, light red = copper, dark grey 
= carbon, light grey = hydrogen). (E) Cyclic Vol-
tammogram of RM191A solution showing two 
reduction peaks and one oxidation peak. (For inter-
pretation of the references to colour in this figure 
legend, the reader is referred to the Web version of 
this article.)   
Table 1 
Elemental analysis of RM191A.  
Element Cu C H N Na O 
% 11.8 27.46 4.45 7.06 12.0 37.23  
Table 2 









Zinc-EDTA − 9.09 3.02 × 10-10 1.15 × 10-28 1 
RM191A − 9.28 4.67 × 10-10 4.27 × 10-28 3.7  
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RM191A. Since inflammation also contributes to pain [46], we then 
measured the effects of RM191A on pain-associated genes. Several key 
biomarkers of pain, for example, IL-18, BDNF and serotonin receptor 
(HTR2A) were downregulated in NHDF upon RM191A treatment 
(Fig. S2L, Table S3). 
In conclusion, RM191A possesses significant antioxidant and anti- 
inflammatory properties via regulation of ROS, RNS and several key 
signalling pathways. 
3.3. RM191A protects skin against UV-induced oxidative stress and DNA 
damage 
Exposure of skin to UV radiation induces direct DNA damage such as 
generation of cyclobutane pyrimidine dimers (CPD), as well as oxidative 
stress via a dramatic increase in ROS and RNS (Fig. S3B) [47]. Such an 
increase results in characteristic DNA damage, for example, oxidative 
DNA damage in the form of 8-oxo-guanine (8-oxoG) and nitrosative DNA 
damage in the form of 8-nitroguanine (8NGO) [48]. If these DNA lesions 
are inadequately repaired, mutations can occur and may lead to the 
development of skin tumours [48]. We wanted to determine whether 
RM191A, when applied topically to ex vivo human skin, reduced 
UV-induced DNA damage. 
Human skin was either pre-treated with RM191A (RM191A 1), fol-
lowed by exposure to UV radiation, or treated with RM191A (RM191A 
2), immediately after UV exposure. In both cases, RM191A treatment 
post-UV exposure was repeated every 30 min for 3 h incubation period. 
The same treatment protocols were also followed for Vehicle. An active 
form of vitamin D – 1,25-dihydroxyvitamin D3 (1,25D), was used as a 
positive control in these experiments as it has previously been shown 
that topical application of 1,25D reduces UV-induced DNA damage in 
human skin cells, human skin explants and human subjects, and reduces 
UV-induced skin tumours in mice [49,50]. Ethanol (1,25D Vehicle) was 
used as a control for 1,25D treatment. Staining for CPD, was virtually 
absent in the isotype control, and the intensity of nuclear staining was 
low in the sham exposed explants, indicating very few CPDs (Fig. S3C). 
This was expected, since exposure to UV was the major source of the 
energy required to produce CPD. Exposure to UV significantly increased 
CPD in UV-1,25D Vehicle or UV-Vehicle groups compared with their 
respective sham controls (compare Fig. 3A and Fig. S3C). Treatment of 
UV-exposed explants with 1,25D or RM191A (RM191A 2) decreased 
CPD by 30% compared to their respective UV-exposed controls 
(Fig. 3A). When pre-treated with RM191A (RM191A 1), CPD decreased 
by 37% compared to its control (Fig. 3A). 
The intensity of nuclear 8-oxoG staining, which is widely recognized 
as a biomarker of oxidative stress [51], was moderate in the sham 
exposed explants treated with 1,25D Vehicle or 1,25D (Fig. S3D) due to 
the fact that culture of the explants engendered some oxidative stress. 
Markedly increased cytoplasmic staining was seen in explants which 
were sham exposed and treated with either Vehicle or RM191A 
(Fig. S3D). Because of this high level of cytoplasmic staining, which was 
also observed in UV exposed explants, for the analysis, two separate 
masks (cytoplasmic and nuclear) were created using the Metamorph 
image analysis program and only the nuclear staining was imaged, so as 
not to include this strong background, non-specific cytoplasmic stain. 
Exposure to UV significantly increased nuclear 8-oxoG in both the UV-1, 
25D Vehicle and UV-Vehicle groups compared with their respective 
sham controls (compare Fig. S3D and Fig. 3B). Treatment of UV-exposed 
explants with 1,25D decreased nuclear 8-oxoG by 27% compared to 
their UV-exposed controls. Treatment with RM191A (RM191A 2) was 
found to decrease 8-oxoG levels by 33%, and the RM191A pre-treated 
group (RM191A 1) was found to have 55% less 8-oxoG, when 
compared to UV-exposed controls (Fig. 3B). Interestingly, oxidative 
DNA damage in the nuclei of epidermal cells was lower in 
RM191A-treated sham explants compared to Vehicle-treated sham 
Fig. 2. RM191A has potent antioxidant and anti-inflammatory properties. 
(A) Comparison of superoxide scavenging activities of both bovine SOD and RM191A between 1.6 and 40 μM concentration at 560 nm (n = 3). (B) Dose-response 
curve of RM191A for N27 cells, as measured by PI exclusion (PI -ve) in flow cytometry (n = 6). The median lethal dose (LD50) is 210 μg/mL. (C) Percentage of live 
N27 cells, as measured by PI exclusion (PI -ve) in flow cytometry, exposed to 200 μM hydrogen peroxide for 30 min and then treated with 21 μg/mL RM191A or 
Vehicle for 4 h (n = 6). (D) Amount of nitrous oxide (NO) generated by RAW 264.7 cells upon LPS (10 ng/mL) stimulation, followed by treatment with RM191A (2.1 
μg/mL) or Vehicle for 24 h (n = 6). NO level was determined by measuring the nitrite in culture medium using Griess reagent. (E) Relative IL-1β, IL-6, TNF-α mRNA 
levels in RAW 264.7 cells upon LPS (10 ng/mL) stimulation, followed by treatment with RM191A (2.1 μg/mL) or Vehicle for 24 h (n = 3). HPRT gene was used as a 
reference. (F) Amount of IL-1β secreted in the culture medium, upon LPS stimulation of RAW 264.7 cells, followed by treatment with RM191A (2.1 μg/mL) or Vehicle 
for 24 h (n = 4). 
Data expressed as mean ± SEM. **p < 0.005, ***p < 0.0005 and ****p < 0.00005 by t-test. 
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wells, indicating that RM191A was able to reduce even base-level 
oxidative damage. There were far fewer cells in the dermis of the ex-
plants, but an analysis was performed on the intensity of staining in the 
nuclei of cells of the upper dermis. Nuclear staining for 8-oxoG was 
overall lower in the dermis of sham exposed explants than in 
UV-exposed explants, but it was not negligible (Fig. 3B). Pre-treatment 
of sham explants with RM191A significantly reduced 8-oxoG staining. 
Nuclear stain for 8-oxoG was significantly increased in the dermis in 1, 
25D Vehicle and Vehicle treated UV-exposed explants, compared with 
sham exposed controls, though the fold increase with UV was not as 
great as seen in the epidermis, probably reflecting reduced penetration 
of UV into the dermis. Nevertheless, as shown in Fig. 3B, each of the 
active treatments significantly reduced 8-oxoG in the dermis. 
Similar to 8-oxoG staining, exposure to UV significantly increased 
nuclear 8NGO staining in UV-1,25D Vehicle and UV-Vehicle groups, in 
both the epidermis and dermis, compared with their respective sham 
controls (compare Fig. S3E and Fig. 3C). As shown in Fig. 3C, treatment 
of UV-exposed explants with 1,25D or with RM191A using either pro-
tocol significantly decreased 8NGO compared with their UV-exposed 
controls. Again, pre-treatment of UV-exposed explants with RM191A 
was more effective at reducing nitrosative DNA damage than RM191A 
post-treatment. 
In conclusion, RM191A was effective in attenuating UV-induced 
oxidative stress and DNA damage in skin. 
3.4. RM191A is non-toxic, non-teratogenic and readily bioavailable in 
mice 
After determining the biological activities of RM191A in cells and 
skin explants, we sought to determine if these effects can translate in 
vivo. Firstly, we used a mouse model to test if RM191A has any toxicity 
in animals. The dorsal surfaces of 12-week-old male mice were shaved 
and 50 μL of RM191A at different doses (0.19–1.9 mL/kg body weight) 
was applied topically daily for 4 days. We found that there were no 
significant changes in the body weight or tissue weights of these animals 
compared to Vehicle control after 4 days of topical treatment (Fig. 4A, 
Table S4), implying that short-term treatment of RM191A is well 
tolerated in mice up to a concentration of 1.9 mL/kg body weight. 
Next, we studied if RM191A was also well tolerated over long-term 
treatment. As previously, the dorsal area of 8-week-old mice was 
shaved, and the animals were either left untreated or treated topically 
daily with 50 μL of Vehicle or RM191A at 0.19 mL/kg body weight for 
29 days. No significant changes in body weight, water intake or food 
intake were observed between the three groups (Fig. 4B, Fig. S4A). The 
fat content, lean mass and water content, as measured using EchoMRI, 
were similar among these three groups (Fig. S4B). After confirming that 
RM191A treatment did not have any adverse impact on the general 
health of mice, we explored if its exposure altered the behaviour of mice. 
In a standard rotarod test, the animals from all three groups performed 
equally well, indicating no significant impact on the motor coordination 
of mice (Fig. S4C). Both Vehicle and RM191A-treated groups exhibited 
higher spontaneous rearing behaviour compared to the untreated group 
(Fig. S4D). Although this increase was not significant, it implied that the 
Vehicle might improve exploratory behaviour of mice. In order to 
confirm that there was no overt toxicity in the tissue of various organs, 
wet tissue weights were measured, and no differences between treated 
and control groups were observed (Table S5). Furthermore, histological 
analyses of these tissues by hematoxylin and eosin (H&E) staining 
showed normal morphology across all groups (Fig. S4E). 
Following up on the results from the toxicity studies and skin explant 
Fig. 3. RM191A protects against UV-induced oxida-
tive stress and DNA damage. 
(A) Representative images of immunohistochemical 
staining of cyclobutane pyrimidine dimers (CPDs) in 
human skin explants from UV-exposed explants 
treated with 1,25-dihydroxyvitamin D3 (1,25D), 
1,25D Vehicle, RM191A (Protocols 1 and 2) or 
Vehicle (Protocols 1 and 2) for 3 h. Analysis of CPDs 
in epidermis of skin explants are shown at the bottom. 
(B) Representative images of immunohistochemical 
staining of 8-oxo-guanine (8-oxoG) in human skin 
explants from UV-exposed explants. Analysis of 8- 
oxoG in epidermis and dermis of skin explants are 
shown below. (C) Representative images of immu-
nohistochemical staining of 8-nitroguanine (8NGO) 
in human skin explants from UV-exposed explants. 
Analysis of 8NGO in epidermis and dermis of skin 
explants are shown below. The magnified (120X) 
images of each staining are shown in the insets. The 
red stain in the 8-oxoG is in the cytoplasm and the 
nuclei in the RM191A-treated groups are consider-
ably less stained. 
Data expressed as mean ± SEM. **p < 0.001 and NS 
= not significant by One-way ANOVA between data 
sets (n = 3 explants per data point). (For interpreta-
tion of the references to colour in this figure legend, 
the reader is referred to the Web version of this 
article.)   
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experiments, we further explored RM191A’s ability to penetrate 
through the skin into the body. The primary goal was to determine 
whether or not RM191A remained on the skin where it could be washed 
away, or if it penetrated through the skin into the blood. To gain these 
insights, we applied 50 μL of RM191A (1.9 mL/kg body weight) topi-
cally to the shaved dorsal surfaces of 8-week-old mice and measured 
total copper content in different animal tissues at different time points 
using ICP-MS. As expected, the amount of copper in the skin steadily 
increased within 15 min and stayed steady up to 2 h following RM191A 
treatment (Fig. 4C). There was also a significant increase in copper levels 
in internal tissues, including liver, lymph nodes and kidney (Fig. 4D and 
E, Fig. S4F), which implied that topically applied RM191A was able to 
penetrate through the skin layers and into the bloodstream (Fig. S4G). 
The ICP-MS results demonstrated that the copper in RM191A follows the 
common mammalian metabolic route, with most of the copper being 
metabolized by the liver, the remainder by the kidneys and was excreted 
within one hour via the faeces (Fig. 4F) and urine (Fig. S4H). Moreover, 
the copper was cleared from the body within 24 h as its levels in tissues 
and blood collected 24 h after RM191A application reduced to the same 
level as the control group at this time point (Table 3). The changes in 
brain copper levels indicated that RM191A might be able to cross the 
blood-brain-barrier (Fig. S4I). This was further investigated using a 
standard in vitro model for human blood-brain-barrier transmission 
which demonstrated that 50.79% of RM191A at 168 μg/mL concentra-
tion crossed the BBB in 2 h, and 95.65% crossed the BBB within 6 h 
(Fig. S4J). 
Since excess copper levels have been associated with birth defects 
because of oxidative damage caused by accumulation of copper in utero 
[52], we assessed the teratogenic effects of RM191A. Pregnant mice 
were topically treated or untreated daily with 50 μL of Vehicle or 
RM191A (2.1 mg/mL) until gestational day 18 and the pups were ana-
lysed. In all three groups, no differences in the number of litters, their 
weight or maternal weight gain were observed (Fig. S4K). Morpholog-
ical analysis of the pups using μ-CT demonstrated no overt skeletal de-
fects, indicating that RM191A did not have any adverse effects on 
embryonic development (Fig. S4LL). Overall, RM191A was found to be 
well-tolerated in mice at varying concentrations and was readily 
distributed systemically upon topical application. 
3.5. RM191A attenuates skin inflammation, improves wound healing and 
reduces age-associated oxidative stress in mice 
Our previous in vitro data demonstrated that RM191A exhibits potent 
anti-inflammatory activity via suppression of ROS/RNS overproduction 
and downregulation of various pro-inflammatory signalling pathways. 
To test this in vivo, we employed a TPA (12-O-tetradecanoylphorbol-13- 
acetate)-induced mouse ear edema model to evaluate the anti- 
inflammatory activity of RM191A in mice [53]. TPA application 
increased the ear weight of Vehicle-treated mice by 133% compared to 
acetone-treated control (Fig. 5A). When the mice were treated with 
RM191A (50 μL of 2.1 mg/mL), there was only a 35% increase in ear 
weight after TPA application. H&E staining of TPA-exposed ear 
cross-sections exhibited a 3-fold increase in ear thickening in 
Vehicle-treated group, but only 1.4-fold increase in RM191A-treated 
mice when compared to acetone-treated mice (Fig. 5B). TPA-induced 
ear edema is also characterized by an influx of immune cells such as 
leukocytes and mast cells, which markedly enhance the inflammatory 
response [54]. Upon closer examination of the H&E stains, we observed 
a 16-fold increase in the number of leukocytes in TPA/Vehicle-treated 
mouse ears and 6-fold increase in TPA/RM191A-treated group 
compared to acetone-treated group (Fig. 5B). The number of mast cells 
was detected by toluidine blue staining of the ear sections. Similar to 
leukocytes, mast cell numbers increased by 2.7 times in 
TPA/Vehicle-treated group compared to acetone-treated group, but only 
1.3 times in TPA/RM191A-treated group (Fig. 5C). As we have shown 
previously (Fig. 2D) that activation of immune cells involves the release 
of NO, we measured the NO levels in ear tissue homogenates from these 
mice. Consistent with this, TPA/Vehicle and TPA/RM191A-treated 
groups had 2.8 and 1.8-fold increase in NO level respectively, 
compared to acetone-treated group (Fig. 5D). 
Next, we tested the effect of RM191A in wound regeneration in mice. 
A circular wound of 10 mm diameter was created on the dorsal surfaces 
of 12-week-old male mice, after which 50 μL of RM191A (2.1 mg/mL) or 
Vehicle was topically applied every 2 days to the wound area. Only two 
days after the start of RM191A treatment, 31% wound regeneration was 
observed in RM191A-treated group compared to only 12% wound 
closure in the control group (Fig. 5E). After 12 days, 93% of the skin was 
regenerated in the RM191A-treated animals, whereas 77% of the wound 
area was healed in Vehicle-treated mice. H&E staining of the wound 
areas at 12 days showed regeneration of both epidermis and dermis 
layers in RM191A-treated group, whereas incomplete restoration of skin 
layers was observed in the Vehicle-treated group. These results were 
corroborated by reduction in epidermal gap, increase in epidermal 
Fig. 4. RM191A is non-toxic and readily 
bioavailable in mice. (A) Body weights (g) of 
mice treated daily with different topical 
doses of RM191A or Vehicle for 4 days (n =
5). (B) Body weights (g) of mice treated daily 
with topical doses of RM191A (0.19 mL/kg) 
or Vehicle for 29 days (n = 9). Copper levels 
in (C) skin, (D) liver, (E) lymph nodes and 
(F) faeces of mice treated with RM191A (50 
μL, 1.9 mL/kg body weight), harvested over 
different time points and measured using 
ICP-MS (n = 4 per time point). 
Data expressed as mean ± SEM. *p < 0.05, 
**p < 0.005, ***p < 0.0005 and ****p <
0.00005 by One-way ANOVA.   
Table 3 
Copper contents (ppb/μLa or ppb/gb) in plasma and tissues 24 h after 
RM191A or Vehicle treatment in mice.   
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thickness and enhanced tissue granulation area of the skin areas of the 
RM191A-treated group when compared to the control group (Fig. 5F). 
Moreover, Masson’s Trichrome staining revealed higher collagen 
deposition in the RM191A-treated dermal layer, compared to their 
control (Fig. 5G). Transition from the inflammatory phase to the pro-
liferative phase is critical for proper wound healing, however, prolonged 
inflammation is detrimental and impedes keratinocyte activation and 
differentiation [55]. The levels of cytokines IL-1β, GRO-α, IL-6 and 
MCP-1 in the serum were downregulated by 85%, 66%, 90% and 70% 
respectively in RM191A-treated group on Day 12 compared to the 
control (Fig. S5A, S5B), indicating that systemic inflammation was 
suppressed by RM191A, thereby favoring the proliferative phase. 
Finally, we tested if RM191A has any effects on skin aging. RM191A 
or Vehicle was topically applied to 102-week-old female mice for 7 
consecutive days. Overall skin morphology as assessed using H&E 
staining was similar between the two groups (Fig. S5C). One of the 
hallmarks of skin aging is accumulation of ROS and RNS. When the NO 
concentration was determined in skin lysates, the RM191A-treated 
group exhibited lower NO levels compared to the control (Fig. 5H), 
implying a beneficial role of RM191A in reducing oxidative stress in 
aged skin. Next, we determined if RM191A affects mast cells in the 
dermis as it has been established that mast cells accumulate in the skin 
with increasing age and contribute to skin aging [56]. As shown in 
Fig. 5I, RM191A treatment significantly reduced the number of mast 
cells compared to the control. The combined results of these analyses led 
us to conclude that RM191A is effective in reducing the negative impacts 
of oxidative stress and inflammation in inflammatory-driven skin dis-
orders, is regenerative of skin in wound healing, and is geroprotective 
when applied to skin. 
4. Discussion 
Native SODs are protective against various oxidative stress-mediated 
skin disorders. This fact has invoked interest in SOD mimetics for ther-
apeutic applications. Among the various classes of SOD mimetics, only 
manganese porphyrin complexes have shown promise in clinical trials 
[57,58]. This is likely due to the fact that unlike previously reported iron 
and copper coordination complexes, manganese-based SOD mimetics 
have typically shown lower toxicity, higher activity and increased sta-
bility. RM191A is the next generation copper-based SOD mimetic that is 
highly stable and whose activity surpasses native SOD’s abilities to 
scavenge free radicals and exceeds most of the manganese-based 
SOD-mimetics. There are several reasons for RM191A’s high SOD-like 
activity. Each molecule of RM191A can react with three O2. - ions while 
reducing Cu2+-Cu3+ to Cu+-Cu+, whereas Mn2+-based SOD-mimetics 
can react with one O2. - ion (Fig. S2M). Moreover, the reduction poten-
tial indicates that the kcat for Cu3+/Cu2+ reduction is likely to be higher 
than that of Cu2+/Cu+ reduction, although this entails further investi-
gation. Furthermore, in cells RM191A upregulates various antioxidant 
genes, such as heme oxygenase, heat shock protein and thioredoxin 
reductase, and downregulates pro-inflammatory cytokines, including 
IL-1β, IL-6 and TNF-α, which can further boost its antioxidant capacity. 
Despite its water solubility, RM191A was able to penetrate the skin 
and distribute into different internal organs via the bloodstream. Our 
toxicity results demonstrated that RM191A is well-tolerated in animals. 
A 26 g mouse can tolerate up to 50 μL of topical RM191A with no side 
effects. This is equivalent to 144 mL applied to the skin of a 75 kg 
human. We have further found that RM191A is stable in light and heat 
up to 30 ◦C for more than 12 months and that RM191A remains active 
and safe in a topical hydrogel formulation over this timeframe. As far as 
we are aware, all previous work identifying the biological activities of 
copper, including its molecular mechanisms, its role in oxidative stress, 
inflammation, immunomodulation, geroprotection and its homeostasis, 
specifically relate to Cu2+ as it would normally be present in the body 
[59–62]. As such, the biological activity of a Cu3+ containing coordi-
nation complex as is present in RM191A is reported here for the first 
time. 
Topical RM191A shows promise as a photoprotective agent in human 
skin and was at least as active as 1,25D, generally acknowledged for its 
photoprotective properties [35,48–50,53]. One of the obvious reasons 
for this reduction in DNA damage is the scavenging of ROS and RNS by 
RM191A, although their levels were not directly tested in the human 
skin explants. This may even explain the lower CPD after 3 h, since ROS 
and RNS damage DNA repair enzymes and thus inhibit DNA repair 
[63–65]. Also, RM191A may reduce DNA damage by other mechanisms, 
such as increasing energy available for DNA repair, upregulating DNA 
repair enzymes or enhancing mitochondrial repair [35]. However, to 
verify this and other results it will be necessary to repeat this study in 
explants prepared from a range of donors with different skin types. 
Inadequately repaired DNA damage is a key factor leading to mutations 
and then to UV-induced skin tumours as well as photo-aging [48]. It 
would be worth testing whether RM191A application in a chronic 
UV-exposure model reduces skin tumours and/or photo-aging in the UV 
exposed areas. 
The topical application of the RM191A demonstrated remarkable 
inhibition of inflammation in the TPA mouse ear model, which has 
significant implications for human use for the treatment of both acute 
and chronic inflammatory-driven diseases including skin conditions like 
psoriasis [66]. Similar to LPS, immune cell influx and subsequent 
ROS/RNS generation by TPA can activate the inflammatory cascade 
[67], which we have found is significantly inhibited by RM191A. The 
direct involvement of RM191A in downregulating inflammatory path-
ways was corroborated by gene expression analysis in RAW and NHDF, 
where RM191A inhibited the expression of many genes reported to be 
involved in skin inflammation. It is possible that the anti-inflammatory 
properties of RM191A are partly mediated by its ROS/RNS-scavenging 
activity. Although RM191A treatment demonstrated marked improve-
ment in the healing rate of large, full-thickness excisional wounds in 
mice, the mechanism is not very clear to us as wound healing response is 
known to be orchestrated by retrograde inflammation and ROS 
Fig. 5. RM191A attenuates skin inflammation, improves wound healing and reduces age-associated oxidative stress in mice. 
(A) Ear weights of mice treated with ± TPA (6 μg in 20 μL acetone), and with RM191A (50 μL of 2.1 mg/mL) or Vehicle (n = 6). (B) Representative H&E staining 
images of ear sections from acetone/Vehicle, TPA/Vehicle and TPA/RM191A treated mice. The magnified views of selected ear areas (black boxes) are shown at the 
bottom. The arrowheads indicate the infiltrated leukocytes. Quantification of ear thickness and number of infiltrated leukocytes are shown in the right (n = 4). (C) 
Representative Toluidine blue stains of ear sections from acetone/Vehicle, TPA/Vehicle and TPA/RM191A treated mice. The arrowheads indicate mast cells. 
Quantification of number of mast cells are shown in the right (n = 3). (D) NO production in ear tissue homogenates of acetone/Vehicle, TPA/Vehicle and TPA/ 
RM191A treated mice (n = 4). (E) Representative images of wound areas on different days in RM191A (50 μL of 2.1 mg/mL) or Vehicle treated mice. The percentage 
wound closure is shown (n = 9). (F) Representative H&E staining images of wound areas in RM191A or Vehicle treated mice on Day 12. The arrowheads indicate the 
epidermal edges of the wound and white dotted lines indicate epidermal area (E: epidermis, D: dermis). The magnified view of the highlighted (black box) area is 
shown in the right. Quantification of epidermal gap, epidermal thickness and tissue granulation area are shown (n = 6). (G) Representative Masson’s Trichrome 
staining images of dermal regions in regenerated skin from RM191A or Vehicle treated mice. Quantification of collagen (blue) content is shown (n = 8). (H) NO 
production in dorsal skin samples of mice (102-week-old) treated with RM191A or Vehicle for 7 days (n = 4). (I) Representative Toluidine blue stains of skin sections 
and mast cells numbers from mice (102-week-old) treated with RM191A or Vehicle for 7 days (n = 4). 
Data expressed as mean ± SEM. *p < 0.05, **p < 0.005, ***p < 0.0005 and ****p < 0.00005 by t-test or One-way ANOVA. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the Web version of this article.) 
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generation [68,69]. One of the possibilities is that RM191A facilitates 
the generation of new tissues (and collagen synthesis) by attenuating 
unwanted inflammation, as evident from the reduction in systemic 
inflammation in the late stage of wound healing, thereby accelerating 
the transition from inflammatory phase to proliferative phase. It will be 
interesting to investigate how RM191A performs in chronic non-healing 
wounds, diabetic ulcers, burns, limb damage and lacerations. Short-term 
application of RM191A reduced age-associated oxidative stress in skin, 
implying a geroprotective role of RM191A. In the next stage of our 
research we will be exploring the effects of long-term application of 
RM191A for the treatment of different age-related skin disorders. 
One of the notable findings of our research was the significant, 
beneficial immunomodulation by RM191A, especially suppression of 
mast cells during skin inflammation and aging. Mast cells are innate 
immune cells resident in tissues, which store preformed inflammatory 
mediators in cytoplasmatic secretory granules which are released 
immediately after activation. Mast cells are the main cell type involved 
in allergic reactions, and are also associated with the adaptive immune 
response, including inflammatory and neurodegenerative diseases, 
traumatic brain injury, stroke, and stress disorders [70,71]. Mast cells 
are also becoming an important target for anti-aging therapy. RM191A 
is therefore likely to have a therapeutically beneficial effect on multiple 
diseases by targeting mast cell activity. 
RM191A’s ability to reduce oxidative stress, inflammation and 
modulate pain-associated biomarkers indicates that RM191A may have 
the potential to attenuate chronic pain. Although measurement of pain 
was beyond the scope of this study, RM191A is currently the subject of a 
Phase II human clinical trial for the treatment of neuropathic pain 
(HREC/16/HAWKE/483). In addition to demonstrating robust antioxi-
dant and anti-inflammatory properties, RM191A might also facilitate 
the incorporation of copper into SOD1 and SOD3, ceruloplasmin and 
tissue repair enzymes - lysyl oxidase and elastase, which in turn can 
accelerate healing and inhibit inflammation. A similar mechanism has 
been proposed for Cu-ATSM, which is currently in clinical trial for motor 
neurone disease (MND) [72,73]. It may also be that RM191A is pro-
tective of mitochondria by eliminating ROS and RNS before they can 
cause oxidative damage, effectively preserving normal cell signalling 
and maintaining the integrity of the mitochondria. 
Interestingly and perhaps importantly, it is now recognized that a 
“cytokine storm”, predominantly driven by IL-1β, IL-6 and TNFα is a 
hallmark of the onset of severe COVID-19 symptoms. We have, in our 
work here, demonstrated that this same cytokine set is meaningfully 
reduced in the bloodstream by RM191A topical treatment. Finally, 
oxidative stress has been linked to a multitude of human diseases and 
conditions, including aging, bipolar disorder, cancer, chronic morphine 
intolerance, diabetes, eye diseases, fibromyalgia, ischemia, pain, radi-
ation injury, reperfusion-related injuries – for example heart attack, 
stroke, and organ dysfunction; as well as neurodegenerative disorders 
like Alzheimer’s, Parkinson’s, MND, multiple sclerosis and epilepsy, to 
mention only a few [74]. RM191A’s significant safety profile, its ability 
to neutralize ROS and RNS, simultaneously diminish or eliminate the 
inflammatory responses and easy bioavailability, sets it apart as a new 
therapeutic and means that it likely has significant benefit in the treat-
ment of a wide variety of human diseases/conditions. 
5. Conclusion 
RM191A is a novel small molecule SOD mimetic that demonstrated 
significant SOD-like antioxidant and anti-inflammatory activities. These 
combined actions are likely the result of its unique, stable Cu2+/Cu3+
dimers. RM191A exhibited protective effects towards a wide range of 
cells against oxidative stress by suppressing ROS and RNS levels and via 
modulating the expression of several key genes associated with oxida-
tive stress and inflammation. The topical application of RM191A bene-
ficially and significantly reduced three types of UV-induced DNA 
damage in human skin explants in the epidermis and in the dermis. This 
reduction in DNA damage was similar to that produced by a well- 
established photoprotective agent, 1,25D. RM191A easily penetrated 
the skin layers and was readily distributed systemically throughout the 
body in mice. Both short-term and long-term dosing of RM191A did not 
exhibit any adverse effects in mice. It’s topical application significantly 
reduced TPA-induced ear inflammation, accelerated excisional wound 
repair and diminished skin aging in mice. In conclusion, RM191A rep-
resents a new class of SOD mimetic which through its prodigious ROS/ 
RNS sequestering, anti-inflammatory activity, and immunomodulation 
exhibits beneficial effects in various skin disorders. 
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